Autophagy is far more than cellular housekeeping. It is a dynamic, evolutionarily ancient stress-response pathway that cells deploy when nutrients are scarce, when mitochondria are damaged, or when misfolded proteins accumulate. Mechanistically, the process begins when the ULK1 complex, regulated by the nutrient-sensing kinase mTORC1, initiates formation of a double-membraned phagophore. Beclin-1 and the VPS34 lipid kinase then generate phosphatidylinositol-3-phosphate to drive membrane expansion, while Atg12-Atg5 conjugates and Atg8-family proteins such as LC3 decorate the growing autophagosomal membrane. The completed autophagosome travels along dynein motor tracks to fuse with lysosomes, where its cargo is enzymatically dismantled and its building blocks returned to the cytoplasm for reuse.

In bone, this recycling pathway is not a background utility but a central regulator of cellular identity and survival. The review surveys evidence that autophagy functions distinctly in each of the four major bone cell types. In osteoclasts, the giant multinucleated cells that dissolve mineralized matrix, autophagy proteins contribute to the secretory machinery that builds the ruffled border, the specialized resorptive apparatus through which the cell pumps acid and proteases onto bone surfaces. In osteoblasts, the bone-forming cells, autophagy supports the enormous biosynthetic burden of producing collagen and mineral, and mice lacking autophagy in the osteoblast lineage develop low bone mass. In osteocytes, the embedded mechanosensory cells that orchestrate remodeling, autophagy declines with aging, and its experimental suppression in mice produces a skeletal phenotype that mimics accelerated aging.

Bone marrow mesenchymal stem cells add another dimension, because their fate determines whether the skeleton gains or loses material. These progenitors can differentiate into osteoblasts or into adipocytes, and in osteoporosis the balance tips toward fat. Studies cited in the review show that autophagy maintains the osteogenic potential and vitality of these stem cells, protecting them against the estrogen deficiency that drives postmenopausal bone loss, and that promoting autophagy in stem cells derived from osteoporotic vertebrae enhances their differentiation into bone-forming cells. Conversely, autophagy also guards against cellular senescence during skeletal aging, positioning the pathway as a guardian of the bone-forming reservoir itself.

Enter the non-coding RNAs, a diverse family of RNA molecules that are transcribed from the genome but never translated into proteins. MicroRNAs, roughly 20 to 22 nucleotides long, bind complementary sequences in messenger RNAs and silence them. Long non-coding RNAs, which can span thousands of nucleotides, act as epigenetic modulators, scaffolds and decoys. Circular RNAs, covalently closed loops generated by back-splicing, are exceptionally stable and often function as molecular sponges that sequester microRNAs. Together these molecules form competing endogenous RNA networks in which lncRNAs and circRNAs soak up microRNAs, thereby releasing the messenger RNAs those microRNAs would otherwise repress. It is within these networks, the review argues, that autophagy in bone cells is fine-tuned.

The mechanistic examples are striking. MicroRNA-20a suppresses the autophagy protein ATG16L1 during hypoxia-induced osteoclast differentiation, thereby influencing how much bone gets resorbed. MicroRNA-199a-3p mediates estrogen’s effects on autophagy in osteocyte-like cells through the IGF-1/mTOR pathway, linking a sex hormone directly to the recycling machinery. MicroRNA-155 induces autophagy in osteoclasts by targeting a component of inflammatory signaling, while microRNA-152-5p suppresses osteogenic differentiation by restraining ATG14-mediated autophagy in mesenchymal stem cells. On the long non-coding RNA side, SNHG14 activates autophagy through the miR-493-5p/Mef2c axis to slow osteoporosis progression, TUG1 promotes osteogenic differentiation via the AMPK/mTOR/autophagy pathway, and NEAT1 appears in multiple networks, including a competing endogenous RNA circuit involving miR-466f-3p that governs osteoblast autophagy.

Circular RNAs bring their own twists. Exosomal circHIPK3 released from bone marrow mesenchymal stem cells promotes osteogenic differentiation of target cells via mitophagy, the selective autophagic clearance of damaged mitochondria. Circ_0026827 sponges miR-188-3p to activate Beclin1 and RUNX1 signaling in stem cell differentiation, while circCDK8 regulates osteogenic differentiation and apoptosis under hypoxic conditions by inducing endoplasmic reticulum stress and autophagy. Perhaps most provocatively, a recent study cited in the review shows that Staphylococcus aureus, the bacterium behind devastating bone infections, blocks host autophagy through a circSyk/miR-5106/Sik3 axis, demonstrating that pathogens have learned to hijack precisely these RNA circuits.

The therapeutic implications are considerable, though the review is careful to frame them as emerging rather than established. Because individual microRNAs can be inhibited with antagomirs or mimicked with synthetic duplexes, and because lncRNAs and circRNAs can be targeted with antisense oligonucleotides or small interfering RNAs, the ncRNA-autophagy axes offer druggable nodes upstream of the autophagy core machinery. Natural compounds are already being tested along these lines: luteolin inhibits dexamethasone-induced osteoporosis by activating autophagy through the miR-125b-5p/SIRT3/AMPK/mTOR axis, and traditional herbal extracts appear to inhibit osteoclast autophagy by degrading miR-199. Delivery remains the central challenge, and the review highlights extracellular vesicles, including engineered exosomes loaded with therapeutic RNA and guided by magnetic nanoparticles, as well as reducible nanoparticles designed to transfect hard-to-transfect cells, as promising vehicles for carrying RNA drugs into bone tissue.

What makes this synthesis compelling is its reframing of osteoporosis as a disease of misregulated cellular recycling, not merely of imbalanced remodeling. Estrogen deficiency, glucocorticoid excess, oxidative stress and aging all converge on autophagy, and the non-coding RNA networks appear to be the dials through which these systemic insults are translated into cell-type-specific changes in bone homeostasis. The authors, whose work was supported by the Jiangxi Provincial Natural Science Foundation and related regional programs, emphasize that much of the evidence comes from cell culture and rodent models, and that dose, timing and cell-type specificity will determine whether manipulating these axes helps or harms. Still, the direction is clear: if the next generation of osteoporosis therapies can learn to speak the language of non-coding RNAs, they may finally target the disease at the level where aging itself writes its signature into the skeleton.

Subject of Research: Regulation of autophagy by non-coding RNAs in osteoporosis pathogenesis and therapy

Article Title: Non-coding RNAs regulating autophagy in Osteoporosis: mechanistic insights and therapeutic potential

Article References: Wang, X., Cai, Y., Liu, R., Xiao, Y., Liu, W., & Zhao, K. (2026). Non-coding RNAs regulating autophagy in Osteoporosis: mechanistic insights and therapeutic potential. Molecular Biology Reports, 53(1), Article 1711. https://doi.org/10.1007/s11033-026-12930-4

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12930-4

Keywords: osteoporosis, autophagy, non-coding RNAs, microRNAs, long non-coding RNAs, circular RNAs, osteoblasts, osteoclasts, osteocytes, mesenchymal stem cells, bone homeostasis, RNA therapeutics